Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
- PMID: 31430371
- PMCID: PMC6938599
- DOI: 10.1093/annonc/mdz237
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
Erratum for
-
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.Ann Oncol. 2018 Aug 1;29(8):1843-1852. doi: 10.1093/annonc/mdy229. Ann Oncol. 2018. PMID: 30010756 Free PMC article. Clinical Trial.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources